Help guide our efforts to modernize
Send us your comments by March 14, 2020. Menu

Pembrolizumab in Combination With CRT for LA-SCCHN

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02586207
Recruitment Status : Active, not recruiting
First Posted : October 26, 2015
Last Update Posted : December 9, 2019
Merck Sharp & Dohme Corp.
Information provided by (Responsible Party):
Sanford Health

No Study Results Posted on for this Study
Recruitment Status : Active, not recruiting
Estimated Primary Completion Date : March 2020
Estimated Study Completion Date : September 2023
Seiwert T, Burtness B, Weiss J, Gluck I, Eder JP, Pai SI, et al. A phase IB study of MK-3475 in patients with human papilloma virus (HPV) associated and non-HPV associated head and neck (H/N) cancer. ASCO 2014 Abstract #6011, Jun 2014.